Prothena Current Ratio 2011-2021 | PRTA

Prothena current ratio from 2011 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Prothena Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.41B $0.05B 7.74
2021-03-31 $0.35B $0.02B 15.02
2020-12-31 $0.30B $0.03B 11.58
2020-09-30 $0.32B $0.02B 14.75
2020-06-30 $0.34B $0.02B 18.40
2020-03-31 $0.36B $0.02B 21.05
2019-12-31 $0.38B $0.02B 21.36
2019-09-30 $0.41B $0.03B 12.88
2019-06-30 $0.42B $0.03B 14.95
2019-03-31 $0.42B $0.02B 27.85
2018-12-31 $0.43B $0.02B 28.90
2018-09-30 $0.46B $0.02B 19.34
2018-06-30 $0.49B $0.05B 10.71
2018-03-31 $0.54B $0.04B 15.11
2017-12-31 $0.43B $0.04B 11.41
2017-09-30 $0.47B $0.04B 11.95
2017-06-30 $0.51B $0.04B 12.92
2017-03-31 $0.51B $0.03B 15.27
2016-12-31 $0.39B $0.04B 9.53
2016-09-30 $0.42B $0.04B 11.26
2016-06-30 $0.45B $0.03B 13.47
2016-03-31 $0.48B $0.02B 20.75
2015-12-31 $0.38B $0.02B 16.99
2015-09-30 $0.39B $0.02B 21.21
2015-06-30 $0.41B $0.01B 30.19
2015-03-31 $0.28B $0.01B 29.80
2014-12-31 $0.30B $0.01B 24.85
2014-09-30 $0.31B $0.01B 30.97
2014-06-30 $0.31B $0.01B 27.14
2014-03-31 $0.20B $0.01B 22.27
2013-12-31 $0.18B $0.01B 24.07
2013-09-30 $0.10B $0.01B 13.34
2013-06-30 $0.11B $0.01B 12.51
2013-03-31 $0.12B $0.01B 23.75
2012-12-31 $0.13B $0.00B 72.16
2012-09-30 $0.00B 0.00
2012-06-30 $0.00B 0.00
2012-03-31 $0.00B 0.00
2011-12-31 $0.00B $0.01B 0.01
2010-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.360B $0.001B
Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer's disease. Prothena Corporation plc is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71